AI drug R&D company Genesis receives investment from NVIDIA to accelerate structure-driven drug design
Genesis Therapeutics, an AI drug research and development company, recently announced that it has once again received additional investment from NVentures, the venture capital arm of Nvidia. The specific amount has not been disclosed. This move marks a fu
2024-12-25